Literature DB >> 2880660

Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells.

B Setyono-Han, M S Henkelman, J A Foekens, G M Klijn.   

Abstract

Various hormones and growth factors are involved in the growth regulation of breast (tumor) cells. In this report we show for the first time that an analogue of the neuropeptide somatostatin (Sandostatin) can also influence the proliferation of human breast cancer cells (MCF-7), namely, in an inhibitory fashion. With respect to dose-response relationship a bell-shaped curve was observed with the maximal inhibition of tumor cell growth at a sharply defined amount of Sandostatin (10 nM). The same effects were found with the natural hormone somatostatin-14 and another analogue (CGP 15-425). These results, together with the observation that high affinity binding sites for an iodinated derivative of Sandostatin are present in MCF-7 cells, support the conclusion that somatostatin and analogues act directly on breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2880660

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

2.  Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer.

Authors:  A Manni; A E Boucher; L M Demers; H A Harvey; A Lipton; M A Simmonds; M Bartholomew
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

3.  Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin.

Authors:  B Szende; K Lapis; T W Redding; G Srkalovic; A V Schally
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

4.  A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity.

Authors:  G Kéri; J Erchegyi; A Horváth; I Mezõ; M Idei; T Vántus; A Balogh; Z Vadász; G Bökönyi; J Seprõdi; I Teplán; O Csuka; M Tejeda; D Gaál; Z Szegedi; B Szende; C Roze; H Kalthoff; A Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

Review 5.  An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.

Authors:  W J Gradishar
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

6.  Antiproliferative effects of somatostatin and the somatostatin analog SMS 201-995 on three human breast cancer cell lines.

Authors:  G Scambia; P B Panici; G Baiocchi; L Perrone; S Iacobelli; S Mancuso
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 7.  Somatostatin and analogues in the treatment of cancer. A review.

Authors:  B M Evers; D Parekh; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

8.  Pharmacokinetic study and effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014.

Authors:  J M Kuhn; C Basin; M Mollard; B de Rougé; C Baudoin; R Obach; G Tolis
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 9.  Endogenous morphine/nitric oxide-coupled regulation of cellular physiology and gene expression: implications for cancer biology.

Authors:  George B Stefano; Richard M Kream; Kirk J Mantione; Melinda Sheehan; Patrick Cadet; Wei Zhu; Thomas V Bilfinger; Tobias Esch
Journal:  Semin Cancer Biol       Date:  2007-12-08       Impact factor: 15.707

10.  Antiproliferative effect of octreotide on gastric cancer cells mediated by inhibition of Akt/PKB and telomerase.

Authors:  Shan Gao; Bao-Ping Yu; Yan Li; Wei-Guo Dong; He-Sheng Luo
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.